Form 4 for MNKD MANNKIND CORP

Accepted 2025-05-16 00:00:00 ET · period of report 2025-05-14 · accession 0000950170-25-073800 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DM	2025-05-16	2025-05-14	MNKD	Marasco Dominic	Pres, Endocrine Business Unit	A - Grant	$1.23	+81.4K	311.5K	+35%	+$100.0K
D	2025-05-16	2025-05-14	MNKD	Marasco Dominic	Pres, Endocrine Business Unit	A - Grant	$0.00	+72.5K	72.5K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock, $0.01 Par Value	2025-05-14	A	A	21,929	$4.56	333,429	D	—	—
2	Common	Common Stock, $0.01 Par Value	2025-05-14	A	A	59,500	$0.00	311,500	D	—	—
3	Derivative	Performance Restricted Stock Unit	2025-05-14	A	A	72,500	$0.00	72,500	D	— · — to —	72,500 Common Stock, $0.01 Par Value	(F3) Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. (F4) The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.